National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
NCI Drug Dictionary
Page Options
Print This Page  Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

NCI Responds to Hurricanes

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183
A radioimmunoconjugate consisting of the murine IgG1 monoclonal antibody BW250/183 labeled with yttrium Y 90 with potential radioimmunotherapeutic activity. Yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183 binds to a 95 kD nonspecific cross-reacting antigen (CD66b or NCA-95) on granulocytes, selectively delivering a cytotoxic dose of Y 90 beta radiation to CD66b-expressing cells. CD66b, a member of the carcinoembryonic antigen (CEA) family with an unknown function, appears early in the differentiation of granulopoietic cells and is expressed on the cell surface of almost all human granulocytes and their more mature precursors. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)




Previous:Y-90 OctreoTher, YM598, yoshi-864, yttrium Y 90 anti-CD19 monoclonal antibody BU12, yttrium Y 90 anti-CD45 monoclonal antibody AHN-12
Next:yttrium Y 90 daclizumab, yttrium Y 90 DOTA monoclonal antibody HuAFP31, yttrium Y 90 DOTA monoclonal antibody HuPAM4, yttrium Y 90 glass microspheres, yttrium Y 90 humanized epratuzumab

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov